DISULFIDE CONTAINING THERAPEUTICS

1 . A prodrug having the formula:

wherein,

R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;

R 2 is

halogen, —CCl 3 , —CBr 3 , —CF 3 , —CI 3 , —CHCl 2 , —CHBr 2 , —CHF 2 , —CHI 2 , —CH 2 Cl, —CH 2 Br, —CH 2 F, —CH 2 I, —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl 3 , —OCF 3 , —OCBr 3 , —OCI 3 , —OCHCl 2 , —OCHBr 2 , —OCHI 2 , —OCHF 2 , —OCH 2 Cl, —OCH 2 Br, —OCH 2 I, —OCH 2 F, —N 3 , —SF 5 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; and

R 1 and R 2 may optionally be joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl;

R 3 is a monovalent drug.

2 . The prodrug of claim 1 , wherein R 3 is a BCS class IV drug.

3 . The prodrug of claim 1 , wherein R 3 is a substrate for a P-glycoprotein or CYP3A4.

4 . The prodrug of claim 1 , wherein R 3 is an antibacterial drug, immunomodulator drug, a photosensitizer drug, or chemotherapeutic drug.

5 . The prodrug of 1 , wherein R 3 is a doxorubicin (DOX), paclitaxel (PTX), camptothecin (CPT), gemcitabine (GEM), or AZD8055.

6 . The prodrug of claim 1 , wherein R 1 is substituted or unsubstituted alkyl.

7 . The prodrug of claim 1 , wherein R 1 is unsubstituted alkyl.

8 . The prodrug of claim 1 , wherein R 1 is unsubstituted C 1 -C 4 alkyl.

9 . The prodrug of claim 1 , wherein R 1 and R 2 are joined to form a substituted or unsubstituted heterocycloalkyl.

10 . The prodrug of claim 1 , wherein R 1 and R 2 are joined to form an unsubstituted heterocycloalkyl.

11 . The prodrug of claim 1 , wherein R 2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

12 . The prodrug of claim 1 , wherein R 2 is hydrogen.

13 . The prodrug of claim 1 , wherein R 2 is substituted or unsubstituted alkyl.

14 . The prodrug of claim 1 , wherein R 2 is substituted or unsubstituted aryl.

15 . The prodrug of claim 1 , wherein R 2 is

16 . The prodrug of claim 1 , having the formula:

17 . The prodrug of claim 1 , having the formula:

18 . The prodrug of claim 1 , having the formula:

19 . A composition comprising the prodrug of claim 1 , and a pharmaceutically acceptable excipient.

20 . A method of treating a disease, said method comprising administering a therapeutically effective amount of a prodrug of claim 1 to a subject.